A Multicentre, Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled Study With Open Label Extension to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Active Ulcerative Colitis

Trial Profile

A Multicentre, Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled Study With Open Label Extension to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Active Ulcerative Colitis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2018

At a glance

  • Drugs GSK 2982772 (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Mar 2018 There is change in treatment: GSK2982772 60 mg orally twice daily to 30 mg three times daily. for outcome measures, time frame has also changed from 112 day follow up to 118 day.
    • 06 Jul 2017 Planned End Date changed from 28 Nov 2018 to 10 Apr 2019.
    • 06 Jul 2017 Planned primary completion date changed from 1 Nov 2018 to 10 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top